SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Amazon Explores AI Content Marketplace With Media Publishers 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
CANTON, Mass., March 19, 2018 -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the appointment of Shirley Kuhlmann to the newly created position of Executive Vice President and General Counsel and Secretary, effective March 16, 2018. Ms. Kuhlmann will oversee all legal and compliance matters for the company.
“We are pleased to have Shirley join our leadership team at this exciting time,” said Mike Heffernan, Collegium’s CEO. “Shirley’s previous role at Pepper Hamilton combined with her in-depth knowledge and understanding of Collegium, will bring immediate value as we execute our growth strategy.”
Prior to joining Collegium, Ms. Kuhlmann was a Partner in the Health Sciences Department of Pepper Hamilton LLP, where she served as Collegium’s outside counsel. Ms. Kuhlmann has over a decade of experience working with both private and public companies on a range of commercial and transactional matters, including financings, corporate governance and disclosure matters, and mergers and acquisitions and other business combination transactions. Ms. Kuhlmann holds a B.A. in Economics/Political Science from Columbia University and a J.D. from Emory University School of Law.
“I have been honored to represent Collegium as outside counsel, and I am very excited to be joining the team at this pivotal time in the Company’s development. I look forward to working with this proven management team and executing on Collegium’s mission to become the leader in responsible pain management,” commented Ms. Kuhlmann.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative, differentiated products for patients suffering from pain.
About Xtampza ER
Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Contact:
Alex Dasalla
[email protected]
